Aviva: Upside To Consensus As We Wait Direct Line Acquisition

Aviva's potential acquisition of Direct Line is projected to increase EPS by approximately 15% within two years, supporting a total return exceeding 10%. Q1 2025 results surpassed expectations across life, retirement, and protection sectors, demonstrating strong cash generation and a robust Solvency II ratio. Consequently, EPS projections for 2025-2028 have been raised, reinforcing an overweight rating due to an improved business mix and conservative consensus.

Analysis

Aviva's proposed acquisition of Direct Line presents a significant opportunity for shareholder value enhancement, with management projecting an approximate 15% uplift in earnings per share (EPS) within two years post-completion, potentially supporting a total return exceeding 10%. This strategic M&A activity is underpinned by Aviva's robust current performance, highlighted by Q1 2025 results that surpassed expectations in its core life, retirement, and protection businesses, alongside strong cash generation and a solid Solvency II ratio. These positive developments have led to upward revisions in EPS projections for the 2025-2028 period. The reiterated overweight rating reflects an anticipated improvement in business mix post-acquisition and suggests that current consensus estimates may be conservative, implying further potential for outperformance.

Key Decisions for Investors

• Investors should evaluate the significant EPS accretion potential, projected at approximately 15% within two years, and the anticipated total return exceeding 10% from the proposed Direct Line acquisition.
• Assess Aviva's strong underlying financial health, evidenced by its Q1 2025 outperformance in key segments, robust cash generation, and a solid Solvency II ratio, which collectively support the upgraded EPS outlook for 2025-2028.
• Consider the current overweight rating and analyst rationale—an improved business mix and conservative consensus estimates—as potential indicators of undervaluation or further upside, warranting a review of positions in Aviva.